Acute administration of WAY-181187 (SAX-187) oxalate (3-30 mg/kg, s.c.) significantly increases extracellular GABA concentrations without altering the levels of glutamate or norepinephrine in the rat frontal cortex. Additionally, WAY-181187 oxalate (30 mg/kg, s.c.) produces modest yet significant decreases in cortical dopamine and 5-HT levels[1].